Our Mission
Enabling transformative addiction treatment with personalized brain interventions to overcome triggers and cravings.
Our Story
Founded with a Mission
Founded by Scott Burwell, PhD, Neurotype Inc. aims to revolutionize Substance Use Disorder (SUD) treatment through advanced neuroscience and personalized medicine. Our journey began with a first prize at Yale’s 2019 Innovation to Impact in SUD week.
Innovative Beginnings
Inspired by his experiences at his family’s liquor store, Burwell pursued a PhD in addiction and brain sciences. Frustrated by the gap between research and clinical application, he founded Neurotype Inc. to bring his laboratory findings into practical, personalized treatment tools.
Pioneering Technology
In 2020, Neurotype Inc. received our first Small Business Innovation Research award from the National Institute on Drug Abuse (NIDA) to develop a brain-based biomarker platform for addiction treatment, now patent-pending and in clinical trials.
Objective Assessment
Traditional SUD assessments rely on subjective self-reports. NeuromarkR™ provides an objective measure of drug craving risk, offering clinicians valuable insights to improve treatment and prevent relapse.
Measurement-based Treatments
Neurotype Inc. is developing treatments that integrate brain-based biomarkers into clinical practice. Our neurofeedback-guided therapies aim to reshape the brain’s response to triggers, enhancing long-term recovery.
